Cameron John Reynolds Purchases 139,811 Shares of VolitionRx Limited (NYSE:VNRX) Stock

VolitionRx Limited (NYSE:VNRX) CEO Cameron John Reynolds purchased 139,811 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was bought at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the transaction, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at $1,206,920.28. This trade represents a 7.07 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

VolitionRx Trading Down 2.6 %

NYSE:VNRX opened at $0.57 on Wednesday. The stock has a market cap of $53.28 million, a P/E ratio of -1.60 and a beta of 1.17. The stock’s 50-day moving average is $0.69 and its 200-day moving average is $0.67. VolitionRx Limited has a 1-year low of $0.43 and a 1-year high of $1.23.

Analyst Ratings Changes

A number of research firms have issued reports on VNRX. D. Boral Capital reiterated a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a research report on Tuesday. StockNews.com began coverage on VolitionRx in a research report on Friday, December 6th. They issued a “sell” rating on the stock. Finally, Benchmark reiterated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd.

Institutional Trading of VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Geode Capital Management LLC increased its stake in VolitionRx Limited (NYSE:VNRX) by 15.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 730,448 shares of the company’s stock after acquiring an additional 95,900 shares during the quarter. Geode Capital Management LLC owned about 0.79% of VolitionRx worth $439,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.